BMEA News

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities